Aflatoxin B1 (AFB1) has been postulated to be a hepatocarcinogen in humans, possibly by causing p53 mutations at codon 249. AFB1 is metabolized via the phase I and II detoxification pathways; hence, genetic variation at those loci may predict susceptibility to the effects of AFB1. To test this hypothesis, genetic variation in two AFB1 detoxification genes, epoxide hydrolase (EPHX) and glutathione S-transferase Ml (GSTM1), was contrasted with the presence of serum AFB,-albumin adducts, the presence of hepatocellular carcinoma (HCC), and with p53 codon 249 mutations. Mutant alleles at both loci were significantly overrepresented in individuals with serum AFB1-albumin adducts in a crosssectional study. Mutant alleles of EPHX were significantly overrepresented in persons with HCC, also in a case-control study. The relationship of EPHX to HCC varied by hepatitis B surface antigen status and indicated that a synergistic effect may exist. p53 codon 249 mutations were observed only among HCC patients with one or both high-risk genotypes. These results indicate that individuals with mutant genotypes at EPHX and GSTM1 may be at greater risk of developing AFB1 adducts, p53 mutations, and HCC when exposed to AFB1. Hepatitis B carriers with the high-risk genotypes may be an even greater risk than carriers with low-risk genotypes. These findings support the existence of genetic susceptibility in humans to the environmental carcinogen AFB1 and indicate that there is a synergistic increase in risk of HCC with the combination of hepatitis B virus infection and susceptible genotype.
HCC patients with one or both high-risk genotypes. These results indicate that individuals with mutant genotypes at EPHX and GSTM1 may be at greater risk of developing AFB1 adducts, p53 mutations, and HCC when exposed to AFB1. Hepatitis B carriers with the high-risk genotypes may be an even greater risk than carriers with low-risk genotypes. These findings support the existence of genetic susceptibility in humans to the environmental carcinogen AFB1 and indicate that there is a synergistic increase in risk of HCC with the combination of hepatitis B virus infection and susceptible genotype.
Primary hepatocellular carcinoma (HCC) is a tumor that occurs at high frequencies in east Asia and subSaharan Africa. In those areas of the world, chronic infection with the hepatitis B-virus (HBV) is the best described risk factor; however, only 20-25% of HBV carriers develop HCC. Exposure to the mycotoxin aflatoxin B1 (AFB1) has also been suggested to increase HCC risk (1), in part because in vitro experiments have demonstrated that AFB1 mutagenic metabolites bind to DNA and are capable of inducing G-to-T transversions (2) .
In certain areas of the HCC endemic regions, an unusual mutational hot spot has been reported in the p53 tumor suppressor gene (3) (4) (5) (6) (7) (8) . This mutation, at the third base of codon 249 in exon 7 , is an AGG-to-AGT transversion (arginine to serine). HCCs from other areas of the world have been reported to have markedly lower frequencies of codon 249 mutations (9) (10) (11) (12) (13) (14) (15) (16) . The geographic distribution of these mutations and the similarity to the transversions produced in vitro by AFB1 suggested to investigators that exposure to AFB1 caused the mutations (3, 4) . Recent demonstration of the preferential mutability of codon 249 by rat liver microsome-activated AFB1 in HepG2 cells has supported the hypothesis (17) .
While rates of chronic HBV infection and AFB1 exposure are both elevated in HCC endemic areas, HCC rates in those regions of Asia are an order of magnitude higher than are the rates in areas of Africa with comparable exposures (18) . A possible explanation for the difference in rates may be that individuals in these populations vary in their capacity to detoxify the mutagenic metabolite of AFB1, aflatoxin 8,9-epoxide. Microsomal epoxide hydrolase (EPHX) and glutathione S-transferase Ml (GSTM1) are both involved in AFB1 detoxification in hepatocytes. EPHX detoxifies the epoxide by conversion into 1,2-dihydrodiols and GSTM1 conjugates the epoxide to glutathione (19, 20) . Therefore, lack or diminution of these enzymes might leave more of the epoxide available to bind to DNA. The GSTM1 isozyme is known to be polymorphic in humans as a consequence of a gene deletion (21) . It has been demonstrated that individuals who lack the gene also lack GSTM1 enzymatic activity (22) . EPHX activity varies within populations and several DNA polymorphisms have been described (23) . Recently, a correlation between mutant alleles of EPHX and diminished activity has been reported by Hassett and colleagues (24) . The authors demonstrated, in in vitro expression studies of cDNA, that substitution of His-113 for the more commonly occurring Tyr-113 residue in exon 3 decreased EPHX activity "40%.
To test whether EPHX and GSTM1 genotypes were associated with serum AFB1-albumin adducts, HCC, and p53 codon 249 mutations, studies were conducted in the HCC endemic areas of Ghana and China. The hypotheses tested were that mutant alleles at one or both loci would be associated with increased levels of serum AFB1-albumin adducts, with HCC and with p53 codon 249 mutations. Case and control participants were genotyped for EPHX and GSTM1. Case participants were typed for p53 codon 249 mutations as well in both their tumor and normal tissues.
MATERIALS AND METHODS
DNA Analysis. DNA was extracted from filter cards of control participants from China by the procedure described by McCabe (26) . Briefly, a spot of blood was punched into an Eppendorf tube, which was autoclaved. Four hundred microliters of 10 mM Tris-HCl, pH 8.3/50 mM KCl/2.5 mM MgCl2/0.1% Triton X-100/0.1% gelatin was added. The tube was boiled and spun, and the supernatant was decanted. DNA was extracted from the tissue of Chinese patients by standard techniques (27) and p53 mutation status were determined by x2 analyses and log-linear modeling. Odds ratios (ORs) (the ratio of the odds in favor of the presence of a factor among the cases to the odds in favor of the presence of a factor among the controls) were calculated to determine the strength of the relationships described.
RESULTS
AFB,/Genotype Study. The results of the AFBi/genotype study showed that the men with detectable AFB,-albumin adduct levels (>5 pg/mg) were more likely to have either an EPHX 1/2 or 2/2 genotype (X2 = 5.1; P = 0.02) than were men without detectable levels. Similarly, men who were GSTM1 null (X2 = 4.7; P = 0.03) were more likely to have detectable AFB,-albumin adduct levels than were men who were not GSTM1 null. When the genotypes were combined, 100% of the men with both high-risk genotypes (at least one EPHX-/2 allele; GSTM1 null) had detectable levels of AFBI-albumin adducts, in contrast with only 32% of the men with both low-risk genotypes (EH 1/1; GSTM1 not null) (Table 1) . One-way analyses of variance determined that the mean AFBI-albumin adduct levels were higher in the men with at least one mutant EPHX allele (11.5 vs. 7.08 pg/mg) and in men who were GSTMi null (9.8 vs. 7.5 pg/mg), although neither difference attained statistical significance.
Three of the 49 Ghanaian participants (6%) were positive for HBsAg. The small number in the HBsAg+ group precluded meaningful analysis after stratification on HBsAg status.
HCC/Genotype Study. In accord with the results of the AFB1/genotype study, the frequency of the GSTM1 null genotype was greater among the cases (56%) than the controls (41%) and the difference was statistically significant at P = 0.047 in a one-tailed test ( Table 2 ). The difference in EPHX distributions between the HCC cases and controls was highly significant (Table 3 ) and remained so after adjustment for multiple comparisons (X2 = 8.7; P = 0.01). As hypothesized, the mutant EPHX allele, allele 2, was significantly overrepresented among the cases. The OR associated with having at least one mutant EPHX allele was 3.3, while the OR associated with being GSTM1 null was 1.9. The OR associated with having at least one mutant EPHX allele and being GSTM1 null was 9.4. Sixteen of the control participants were positive for HBsAg (13.8%), in contrast with 37 of the 48 tested case participants (77%). As expected, the association between HBsAg+ and HCC case status was highly significant (X2 = 62; P < 0.0001; OR = 21.0). Given that both HBsAg status and EPHX genotype were related to HCC risk, ORs were calculated for the risk of HCC, given combinations of the two factors (Table  4 ). In contrast with individuals with neither high-risk factor (i.e., HBsAg-/EPHX 1/1), individuals with just the high-risk genotype (i.e., HBsAg-/at least one EPHX-/2 allele) had >3 times the risk of HCC and individuals with just the viral infection (i.e., HBsAg+/EPHX 1/1) had 15 times the risk of HCC. Individuals, however, with both the viral infection and the high-risk genotype had >77 times the risk of HCC of individuals with neither factor. This synergism of the two factors could be explained by an examination of the data in Table 4 . Among the HBsAg-individuals, risk of HCC was not increased until two copies of the EPHX mutant allele were present. Among the HBsAg+ individuals, however, risk of HCC increased in the presence of only one EPHX mutant allele.
Given the synergism of HBV and EPHX genotype in producing risk, an examination of age at diagnosis was done to determine whether individuals with multiple risk factors were likely to develop disease earlier than individuals with fewer factors. Individuals of the highest-risk status, HBsAg+ and EPHX 2/2 genotype, had a mean age at diagnosis of 48 years. In contrast, HBsAg+ individuals with only one mutant EPHX allele and HBsAg-individuals with an EPHX 2/2 genotype had mean ages at diagnosis of 52 years. (Table 5) . Nine of the 10 individuals with p53 codon 249 mutations had been typed for HBsAg and all were HBsAg+ (X2 = 3.2; P = 0.07). There were no differences in p53 mutation rate by sex or age of the case.
To determine whether there were differences in genotype distribution by country, the EPHX and GSTM1 distributions were compared in the Ghanaian participants and Chinese controls. While there was no difference in the GSTM1 null , low risk; T, high risk.
*x2 = 5.1; P = 0.07.
frequencies in the two groups (Table 6 ), the EPHX distributions were significantly different (Table 7) . Sixty-nine percent of the Ghanaian participants had the low-risk EPHX 1/1 genotype in contrast with only 26% of the Chinese control participants (P < 0.0001).
DISCUSSION
In this paper, we report a significant association between EPHX and GSTM1 genotypes and the presence of AFB1 adducts. We also report a significant association between EPHX genotype and HCC. The association between GSTM1 genotype and HCC is suggestive, as are the relationships between the genotypes and p53 codon 249 mutations. An association among detoxification genotypes, AFB1-albumin adducts, and HCC has biologic plausibility. The AFB1 parent compound is not harmful prior to metabolic activation to form AFB1-8,9-epoxide via the phase I detoxification pathway. The epoxide can then be rendered innocuous via phase II detoxification, in which GSTM1 conjugates the epoxide to glutathione and EPHX converts the epoxide into AFB1-dihydrodiol (19, 20) . Alternatively, the epoxide can bind to DNA at the N7 guanine residue. The lack or diminution of the phase II detoxification enzymes would then leave more of the epoxide available to bind to DNA. Therefore, it could be hypothesized that persons who had an impaired ability to detoxify the mutagenic AFB1 metabolite would be more likely to suffer the related effects. Similarly, the association between detoxification genotypes and p53 codon 249 mutations is not entirely unexpected in that GSTM1 and EPHX enzymes remove the AFB1 epoxide speculated to cause the mutations in p53 at codon 249.
The failure to detect a statistically significant relationship between GSTM1 genotype and case/control status may be due to one of several reasons. The most obvious explanation is that a significant association may not exist. The existence of the AFB1/GSTM1 association, however, is some evidence that GSTM1 may be important in AFB1-related HCC. Alternatively, our failure to detect an association may simply be due to an inadequate sample size given that the P value approached significance and the GSTM1 null type can be considered a very Our results indicate that constitutional genotypes at certain detoxification loci may be significant risk factors for HCC. Given that the control Chinese population had a significantly greater number of individuals with a high-risk genotype, but not a significantly greater number of HBsAg+ individuals than the Ghanaian population, these data support the hypotheses that genotype differences may explain HCC rate differences in the two areas. In particular, the difference in the EPHX distributions may be of particular significance.
Genetic susceptibility, in humans, due to the inheritance of a mutation in a tumor suppressor gene, is now well established (33) . From results of this study, we suggest that genetic susceptibility may also occur through an alternative mechanism: inheritance of a genotype that increases the probability of mutations occurring at etiologic loci such as p53. Furthermore, this susceptibility appears to occur in conjunction with exposure to an environmental carcinogen. The identification of an EPHX/GSTM1-AFB1-p53 link in HCC suggests that genetic susceptibilities to the effects of other carcinogens occur among human populations and may be involved in the etiology of common cancers.
